Hyperkalemia | Treatment Algorithms: Claims Data Analysis | US | 2025

Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the management of hyperkalemia remains elusive. The aggressiveness of therapy depends on the rapidity with which hyperkalemia develops and absolute K+ concentration. Clinicians address this condition using two primary strategies: intracellular shift of potassium ions (using IV insulin / glucose or inhaled salbutamol) and promoting potassium excretion (via K+ binders and diuretics). In this report, we delve into the key therapeutic approaches and their application in treating newly diagnosed and recently treated hyperkalemia patients.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hyperkalemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hyperkalemia patients?
• How have K+ binders (Lokelma, and Veltassa) been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of hyperkalemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of hyperkalemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Market covered: United States

Key drugs: Lokelma, Veltassa, Lasix, Ventolin

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.Dashboard featuring interactive visuals, easy navigation, and expanded analyses